In the phase 2b IMPACT trial, up to 42.9% of patients with MASH achieved concurrent liver fat, ALT, and stiffness responses on pemvidutide vs 3.3% on placebo.
Feature|Articles|October 1, 2026
After Decades of Damage and a Pandemic Spike, Where Does Alcohol-Associated Liver Disease Stand?
Fact checked by: Alex Hillenbrand
As drinking declines, Stevan Gonzalez, MD, Frances Lee, MD, and Brian Lee, MD, on the lingering burden of alcohol-associated liver disease.
Advertisement
Advertisement
Over the past two decades,
Related to this article
Post hoc phase 2 data show survodutide improved MASH and fibrosis endpoints across all weight loss categories, including patients losing less than 5%.
TRANSCEND-T2D-2 topline data show retatrutide lowered A1C more and produced over twice the weight loss of semaglutide 2 mg in type 2 diabetes.
Jasmohan Bajaj, MD, MS, joins Nancy Reau, MD, and Kimberly Brown, MD, on who to screen for HE in clinic and how to prepare patients and families.
Juanita Mora, MD, of Chicago Allergy Center discusses strategies from boosters and antiviral prophylaxis to specialist counseling.
Stay updated with the latest healthcare breakthroughs, including 96-week durability data for GSK’s bepirovirsen in hepatitis B, and more.
Topline results presented at The Liver Meeting showed 79% of patients with HDV reached undetectable HDV RNA at 48 weeks with monthly elebsiran plus tobevibart.
End-of-study B-Well data show 91% of patients with chronic hepatitis B who achieved functional cure with bepirovirsen maintained it through Week 96.
Advertisement
Advertisement